Biogen Inc

On May 3, Biogen announced that CEO Michel Vounatsos is stepping down from his role. His net worth is estimated to be over $32 million.

Given how coveted advancements in Alzheimer's research are, these publicly traded stocks can help you impact science and reap returns.

Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.

On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

Today, Biogen (BIIB) and partner Eisai presented highly anticipated detailed study data for their investigational Alzheimer’s drug BAN2401.

Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or “U.S. Moat Index”), once again posted strong results in July.

In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.

In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.

In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

Across the five moat sources (network effect, intangible assets, cost advantage, switching costs, and efficient scale), efficient scale is the most likely to drive a “narrow moat” rating from Morningstar.

In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.

In 1H17, Teva Pharmaceutical’s (TEVA) Copaxone reported revenues of ~$2.1 billion, or ~7% lower YoY (year-over-year).

Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.

Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.

The Phase 3 RADIANCE trial enrolled 1,313 RMS patients and conducted the trial in 21 countries.

In 2016, Pfizer’s (PFE) biosimilar business reported revenues of ~$319 million, compared with $63 million in 2015.

Allergan’s (AGN) business has undergone several changes over the past few years due to acquisitions and divestitures.

Allergan Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: US Specialized Therapeutics, US General Medicine, and International. Stock price performance Allergan’s stock price has risen ~1.4% in 2Q17, and 15.0% year-to-date as of July 7, 2017. […]

Currently, Biogen is conducting 13 clinical studies in early phases and expects promising results from those trials.

Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS’s total revenues in 1Q17.

To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.

Novartis’s (NVS) Innovative Medicines segment contributed ~66.6% to overall 1Q17 revenue, or $7.7 billion.

Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.

Sanofi’s (SNY) 2016 revenues were mainly driven by Sanofi Genzyme and Sanofi Pasteur.

Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.

Sanofi’s (SNY) 4Q16 revenues were mainly driven by Genzyme and Sanofi Pasteur.

The overall contribution from NVS’s Innovative Medicines segment was ~67%, reaching $8.3 billion in 4Q16.

The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.

In addition to being explored as a monotherapy for AD (atopic dermatitis), Regeneron and Sanofi are also researching Dupixent for other indications.

In Phase 3 trials, SOLO 1 and SOLO 2, Regeneron (REGN) and Sanofi (SNY) tested the efficacy of an investigational therapy, Dupixent, compared to a placebo.

Trump’s healthcare agenda During his campaign, Trump came up with a seven-point plan for the healthcare industry. In this plan, he proposed to repeal the Affordable Care Act. Although a complete repeal doesn’t seem feasible, if applied, it would definitely take a toll on hospitals and insurance companies. In the next article, we’ll discuss the severity of […]

In 3Q16, Biogen’s (BIIB) oral multiple sclerosis (or MS) drug, Tecfidera, managed to increase its global market share to ~15%, a year-over-year (or YoY) rise of about 1 point.

The U.S. Food and Drug Administration (or FDA) recently awarded the fast track status to aducanumab following the positive results of Biogen’s pre-clinical research.

BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million.

Wall Street analysts expect Enbrel to earn $3 billion and $2.5 billion from the sale outside US and Canada in fiscal 2016 and 2017, respectively.

After Sanofi’s reorganization, Genzyme now includes products for multiple sclerosis, rare diseases, and oncology. Genzyme’s sales increased ~19.5% in 2Q16.

BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.

Novartis (NVS) has recorded direct product sales of over $1 billion for each of its ten pharmaceutical products in the last year.

Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.